Muscle Relaxant Drugs Market Share

North America Market Forecast

The North America muscle relaxant drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037, backed by the upsurge in healthcare expenditure, low physical activity along with the high prevalence of musculoskeletal conditions affecting people of all ages in the region. According to the American Medical Association’s (AMA) Policy Research Perspective (PRP) report, the National Health Expenditures (NHE) increased by 9.7 percent and became 19.7 percent of GDP in the year 2020.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of muscle relaxant drugs is estimated at USD 3.62 million.

The muscle relaxant drugs market size was valued at USD 3.43 million in 2024 and is poised to cross USD 8.06 million by the end of 2037, registering more than 6.9% CAGR during the forecast period i.e., between 2025-2037. Upsurge in the use of muscle relaxants with other anaesthetics during surgical procedures, increasing sedentary lifestyle and decreasing levels of activity will boost the market growth.

North America is likely to dominate majority industry share by 2037, driven by upsurge in healthcare expenditure, low physical activity along with the high prevalence of musculoskeletal conditions affecting people of all ages in the region.

The major players in the market include AbbVie Inc., Antisense Therapeutics Limited, Sandoz International GmbH, Abbott Laboratories, Pfizer, Inc., Merck & Co., Inc., SteriMax Inc., Vertical Pharmaceuticals, LLC, Instas Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd.

Muscle Relaxant Drugs Market Share